177 related articles for article (PubMed ID: 26336202)
1. Remote Assessment of Cognitive Function in Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease): A Pilot Study of Feasibility and Reliability.
Ragbeer SN; Augustine EF; Mink JW; Thatcher AR; Vierhile AE; Adams HR
J Child Neurol; 2016 Mar; 31(4):481-7. PubMed ID: 26336202
[TBL] [Abstract][Full Text] [Related]
2. The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.
Wibbeler E; Nickel M; Schwering C; Schulz A; Mink JW
Eur J Paediatr Neurol; 2022 May; 38():62-65. PubMed ID: 35427884
[TBL] [Abstract][Full Text] [Related]
3. Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).
Kwon JM; Adams H; Rothberg PG; Augustine EF; Marshall FJ; Deblieck EA; Vierhile A; Beck CA; Newhouse NJ; Cialone J; Levy E; Ramirez-Montealegre D; Dure LS; Rose KR; Mink JW
Neurology; 2011 Nov; 77(20):1801-7. PubMed ID: 22013180
[TBL] [Abstract][Full Text] [Related]
4. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
Drack AV; Miller JN; Pearce DA
J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
[TBL] [Abstract][Full Text] [Related]
5. Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.
de Blieck EA; Augustine EF; Marshall FJ; Adams H; Cialone J; Dure L; Kwon JM; Newhouse N; Rose K; Rothberg PG; Vierhile A; Mink JW;
Contemp Clin Trials; 2013 Jul; 35(2):48-54. PubMed ID: 23628560
[TBL] [Abstract][Full Text] [Related]
6. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
[TBL] [Abstract][Full Text] [Related]
7. A clinical rating scale for Batten disease: reliable and relevant for clinical trials.
Marshall FJ; de Blieck EA; Mink JW; Dure L; Adams H; Messing S; Rothberg PG; Levy E; McDonough T; DeYoung J; Wang M; Ramirez-Montealegre D; Kwon JM; Pearce DA
Neurology; 2005 Jul; 65(2):275-9. PubMed ID: 16043799
[TBL] [Abstract][Full Text] [Related]
8. Gene symbol: CLN3. Disease: Juvenile neuronal ceroid lipofuscinosis (Batten disease).
Leman AR; Pearce DA; Rothberg PG
Hum Genet; 2005 May; 116(6):544. PubMed ID: 15991331
[No Abstract] [Full Text] [Related]
9. Gene symbol: CLN3. Disease: juvenile neuronal ceroid lipofuscinosis (Batten disease).
Leman AR; Pearce DA; Rothberg PG
Hum Genet; 2005 Feb; 116(3):236. PubMed ID: 15818814
[No Abstract] [Full Text] [Related]
10. Juvenile neuronal ceroid lipofuscinosis (Batten disease) CLN3 mutation (Chrom 16p11.2) with different phenotypes in a sibling pair and low intensity in vivo autofluorescence.
Mantel I; Brantley MA; Bellmann C; Robson AG; Holder GE; Taylor A; Anderson G; Moore AT
Klin Monbl Augenheilkd; 2004 May; 221(5):427-30. PubMed ID: 15162299
[TBL] [Abstract][Full Text] [Related]
11. Dissimilar neuropsychiatric presentations of two siblings with juvenile neuronal ceroid lipofuscinosis (Batten disease).
Lee TS; Poon SH; Chang P
J Neuropsychiatry Clin Neurosci; 2010; 22(1):123.E14-5. PubMed ID: 20160229
[No Abstract] [Full Text] [Related]
12. Neuropsychological symptoms of juvenile-onset batten disease: experiences from 2 studies.
Adams HR; Kwon J; Marshall FJ; de Blieck EA; Pearce DA; Mink JW
J Child Neurol; 2007 May; 22(5):621-7. PubMed ID: 17690071
[TBL] [Abstract][Full Text] [Related]
13. Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease).
Adams HR; Beck CA; Levy E; Jordan R; Kwon JM; Marshall FJ; Vierhile A; Augustine EF; de Blieck EA; Pearce DA; Mink JW
Dev Med Child Neurol; 2010 Jul; 52(7):637-43. PubMed ID: 20187884
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive Treatment for Retinal Degeneration in Juvenile Neuronal Ceroid Lipofuscinosis (Juvenile Batten Disease).
Drack AV; Mullins RF; Pfeifer WL; Augustine EF; Stasheff SF; Hong SD
Ophthalmic Genet; 2015; 36(4):359-64. PubMed ID: 24547931
[TBL] [Abstract][Full Text] [Related]
15. A knock-in reporter mouse model for Batten disease reveals predominant expression of Cln3 in visual, limbic and subcortical motor structures.
Ding SL; Tecedor L; Stein CS; Davidson BL
Neurobiol Dis; 2011 Feb; 41(2):237-48. PubMed ID: 20875858
[TBL] [Abstract][Full Text] [Related]
16. Defective lysosomal arginine transport in juvenile Batten disease.
Ramirez-Montealegre D; Pearce DA
Hum Mol Genet; 2005 Dec; 14(23):3759-73. PubMed ID: 16251196
[TBL] [Abstract][Full Text] [Related]
17. A novel mutation af Cln3 associated with delayed-classic juvenile ceroid lipofuscinois and autophagic vacuolar myopathy.
Licchetta L; Bisulli F; Fietz M; Valentino ML; Morbin M; Mostacci B; Oliver KL; Berkovic SF; Tinuper P
Eur J Med Genet; 2015 Oct; 58(10):540-4. PubMed ID: 26360874
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of the major deletion in the Batten disease gene CLN3 by allele specific PCR.
Taschner PE; de Vos N; Breuning MH
J Med Genet; 1997 Nov; 34(11):955-6. PubMed ID: 9391897
[TBL] [Abstract][Full Text] [Related]
19. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).
Sarpong A; Schottmann G; Rüther K; Stoltenburg G; Kohlschütter A; Hübner C; Schuelke M
Clin Genet; 2009 Jul; 76(1):38-45. PubMed ID: 19489875
[TBL] [Abstract][Full Text] [Related]
20. A diagnostic confidence scheme for CLN3 disease.
Masten MC; Corre C; Paciorkowski AR; Vierhile A; Adams HR; Vermilion J; Zimmerman GA; Augustine EF; Mink JW
J Inherit Metab Dis; 2021 Nov; 44(6):1453-1462. PubMed ID: 34453334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
